What’s New in Ontosight® Terminal 1.1 A Complete Guide toRead More
Archives: News
Innoplexus Announces Appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President
Hoboken, New Jersey, September 16, 2019- Innoplexus Inc., a subsidiary of Innoplexus AG, announced today the appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President. Mr. Davlos is a highly accomplished artificial intelligence and machine learning executive with over 20 years of leadership experience. Prior to joining Innoplexus, Mr. Davlos was …
Traum aller Anleger
Innoplexus aus Eschborn und der Vermögensverwalter Acatis aus Frankfurt testen eine neue KI-Maschine für die Geldanlage. Der 21. März 2019 bleibt den Aktionären des Pharmakonzerns Biogen in schmerzhafter Erinnerung. Kurz vor Börsenbeginn hatte der in Cambridge, Massachusetts, aufgehende Stern am Biotech-Himmel die Investoren darüber unterrichtet, dass er eine klinische Studie mit seinem Alzheimer-Präparat „Aducanumab“ abbrechen …
Innoplexus Announces Appointment of Rita Kelley as Senior Vice President and Managing Director, USA
Hoboken, New Jersey, September 12, 2019 – Innoplexus Inc, a subsidiary of Innoplexus AG, Frankfurt, which has developed the most comprehensive, industry validated, AI-powered Drug Discovery and Development platform, announced today the appointment of Rita Kelley as Senior Vice President Corporate Development and Marketing. Rita will also act as Managing Director USA. Ms. Kelley is …
Innoplexus and Cures Within Reach for Cancer Tap the Power of Artificial Intelligence to Find Off-Patent Non-Cancer Drugs That Have Potential to Treat Cancer
Hoboken, NJ, August 5, 2019 – Innoplexus Holdings, Inc., a leader in artificial intelligence (AI) solutions for the life sciences industry, has partnered with the nonprofit Cures Within Reach for Cancer to pave the way for faster and more effective identification of new, affordable cancer treatments among existing non-cancer generic and off-patent drugs. Innoplexus is …
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific AI prediction engine, which recently caught attention by correctly predicting that Biogen’s Alzheimer’s drug aducanumab would fail with 70% to 90% certainty. Allie Nawrat finds out more. In March 2019, Biogen’s long anticipated drug for …
AI CTP engine estimated failure for Biogen’s aducanumab Read More »
Predicting Drug Flops with AI
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific AI prediction engine, which recently caught attention by correctly predicting that Biogen’s Alzheimer’s drug aducanumab would fail with 70% to 90% certainty. Allie Nawrat finds out more. n March 2019, Biogen’s long anticipated drug for …
Google for Healthcare
Gunjan Bhardwaj chose Germany as the place to launch his advanced search and discovery solution. His company assists the healthcare industry by organizing and analyzing vast amounts of data using artificial intelligence.
Lessons Learned from Other Industries
While the auto industry is embracing big data and its opportunities for new services and deep insights, auto companies are wary of security risks that could spark a costly backlash. Automakers can learn a lot from other industries — such as financial services, utilities and health care — that have long been traveling this road. …
Innoplexus Launches Worldwide Academic Access Program for its Flagship Ontosight.ai
Frankfurt, Germany, May 21, 2019 — Innoplexus announced today the launch of Ontosight Academic, a platform that provides academic researchers free access to a vast volume of life sciences data made searchable using machine learning algorithms and other artificial intelligence technologies. Today, academic researchers in life sciences are swamped with millions of publications and theses …
Innoplexus Launches Worldwide Academic Access Program for its Flagship Ontosight.ai Read More »